NCT04090034Recruiting
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine
Source: ClinicalTrials.gov · Last updated 20 Mar 2026
Brief summary (registry, in English)
The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 12 Sept 2019
- Start date
- 28 Mar 2024
- Primary completion date
- 28 Jun 2026
- Lead sponsor
- Methodist Health System
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT04090034
What you commit to
- Study type: Observational
- Planned participants: 50
- From 28 Mar 2024 to the primary completion date, 28 Jun 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Do not meet the Study Inclusion Criteria laid out in section 6.3
Who the study is looking for
- \> 18 years of age
- Diagnosed with gastroenteropancreatic primary NET and has consented to undergo PRRT per the treating physician. Specifically:
- Will consider other primaries on a case by case basis if dotatate scan (+) and meet all other criteria.
- Metastatic or Locally Advanced AND Inoperable
- Clear disease progression on Octreotide over less than 3 years (RECIST 1.1)
- Presence of disease within 24 weeks as identified by PET/CT scans with Ga-68 DOTATATE reporting the Krenning score for low-grade NET and/or PET/CT scans with FDG for transformation to high-grade NET
- Well differentiated on path - Ki67 \< 20%
- Octreotide positive on pathology (if not documented, acceptable if PET/CT imaging shows lesions with Ga-68 DOTATATE uptakeLabs:
- Cr. \<1.7
- Hgb \>8
- WBC \>2K
- Plt \>75K
- Bili \< 3x normal limit
- No Octreotide within 30 days of administration.
- Willing and able to comply with the protocol requirements
- Able to comprehend and sign the Informed Consent Form in English.
Age in the registry: 18 years to - · Sex: All
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Research Institute at Methodist Health System Coordinator of this site? Confirm its status | Dallas | United States | Recruiting |
| Methodist Dallas Medical Center Coordinator of this site? Confirm its status | Dallas | United States | Enrolling by invitation |
This page is information, not medical advice. Discuss any trial with your doctor.